While high-throughput screening (HTS) remains a powerful weapon for hit identification, it is important to be aware of the many alternative tools available to the medicinal chemist for initiating a drug discovery program. No hit identification method is always fruitful; they all have their strengths and weaknesses, and only by judicious integration of hit identification approaches can the chances of success be maximized.
In this webinar, Charles River’s scientists take a look at some of the complementary approaches to HTS from a chemist’s perspective and how these strategies have been successfully applied to real drug discovery programs at Charles River for Charles River’s partners.
Examples of such approaches include:
- Knowledge-based design: using chemistry expertise to make inventive modifications to known bioactive molecules
- In silico screening: using structure and ligand-based approaches to virtually screen large collections of compounds
- Fragment screening via low-throughput biophysical techniques such as SPR and NMR
- Better understand the range of alternative hit-finding approaches to HTS
- Understand how these approaches can be complementary to each other
- View case study examples of how each has been successfully applied to real drug discovery programs
Sam Mann, MChem, PhD, Principal Scientist, Medicinal Chemistry, Charles River Laboratories
Sam Mann graduated from the University of York with a Master of Chemistry degree, having spent a year on exchange at the Université Joseph Fourier in Grenoble, France. He then moved to London to study for a PhD under the supervision of Dr. Tom Sheppard at University College London. His doctoral research focused on the development of new synthetic methodologies involving cyclic oxygen, nitrogen and sulfur acetal derivatives and their applications in palladium (II)-catalysed oxidations, multicomponent reactions and medium ring synthesis.
He later joined Argenta, which became part of Charles River in 2014. Having worked on a variety of drug discovery programs for high profile clients, he quickly progressed to his current position as a principal scientist, leading the medicinal chemistry effort on an early stage oncology project. Dr. Mann has approximately six years’ experience in oncology drug discovery, working primarily on kinase targets.Message Presenter
Who Should Attend?
This webinar is designed for scientists engaged in drug discovery, particularly those responsible for generating new molecular entities and deciding on which combination of techniques to apply such as high throughput screening, primary screening, fragment screening, hit confirmation and characterization.
As your scientific partner and preclinical CRO provider, Charles River provides innovation, flexibility, and efficiency in IND-enabling studies from early discovery research and in vivo pharmacology models through safety assessment. Our unique combination of interdisciplinary, multi-disciplinary drug discovery expertise and unparalleled scope of capabilities in targets, platforms, and therapeutic areas allow us to deliver depth and breadth in science with insight and data you can trust to progress your drug discovery programs at any point along the way, from your very first research question about a molecule to a drug candidates’ first trial in man.